Editas Medicine Inc. (EDIT)

27.86
NASDAQ : Health Technology
Prev Close 27.41
Day Low/High 25.82 / 28.05
52 Wk Low/High 14.01 / 34.37
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 55.00M
Market Cap 1.51B
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'

Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'

You have to be willing to chase if you want to establish new positions.

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.

Editas upgraded at Jefferies

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.